Wenhui Xie

ORCID: 0000-0003-2981-5847
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer, Hypoxia, and Metabolism
  • Lung Cancer Treatments and Mutations
  • RNA modifications and cancer
  • Medical Imaging Techniques and Applications
  • Myasthenia Gravis and Thymoma
  • Epigenetics and DNA Methylation
  • Cancer Research and Treatments
  • Radiopharmaceutical Chemistry and Applications
  • Cancer Genomics and Diagnostics
  • Pituitary Gland Disorders and Treatments
  • Cancer-related gene regulation
  • Glioma Diagnosis and Treatment

Shanghai Chest Hospital
2011-2021

Shanghai University of Medicine and Health Sciences
2020-2021

Shanghai Jiao Tong University
2014-2021

<sup>18</sup>F-FDG PET has been widely used in the management of malignant tumors. Lactate dehydrogenase A (LDHA) plays an important role development, invasion, and metastasis malignancies. However, relationship between accumulation LDHA expression not investigated. <b>Methods:</b> Retrospective analysis was conducted for 51 patients with lung adenocarcinomas who underwent PET. The maximum standardized uptake value LDHA, glucose transporter 1 (GLUT1), hexokinase 2 (HK2) were examined. RNA...

10.2967/jnumed.114.145490 article EN Journal of Nuclear Medicine 2014-10-23

Abstract Protein kinase B (AKT) hyperactivation and de novo lipogenesis are both common in tumor progression. Sterol regulatory element‐binding protein 1 (SREBP1) is the master regulator for lipid metabolism, arginine methyltransferase 5 (PRMT5) an enzyme that can catalyze symmetric dimethyl (SDMA) modification of mature form SREBP1 (mSREBP1) to induce its hyperactivation. Here, we report SDMA‐modified mSREBP1 (mSREBP1‐SDMA) was overexpressed correlated with Ser473‐phosphorylated AKT...

10.1111/cas.14988 article EN cc-by-nc Cancer Science 2021-05-25

To determine whether protein kinase C-iota (PKC-iota) is associated with glucose metabolism in non-small-cell lung cancer (NSCLC) and its regulatory effect on metabolic biological changes observed NSCLC can be mediated by transporter 1 (GLUT1).Forty-five patients underwent combined 18F-fludeoxyglucose (18F-FDG) positron emission tomography computed (PET/CT) before surgery, another eighty-one were followed-up for 1-91 months after tumor resection. The rate of was quantified measuring the...

10.2147/ott.s207211 article EN OncoTargets and Therapy 2019-07-01
Coming Soon ...